1. Academic Validation
  2. Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors

Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors

  • Macromol Biosci. 2023 Oct 15:e2300375. doi: 10.1002/mabi.202300375.
M Tommy Gambles 1 2 Douglas Sborov 3 Paul Shami 3 Jiyuan Yang 1 2 Jindřich Kopeček 1 2 4
Affiliations

Affiliations

  • 1 Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT, 84112, USA.
  • 2 Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
  • 3 Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • 4 Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, 84112, USA.
Abstract

Drug-Free Macromolecular Therapeutics (DFMT) utilizes modified monoclonal Antibodies (or antibody fragments) to generate antigen-crosslinking induced Apoptosis in target cells. DFMT is a two-component system containing a morpholino oligonucleotide (MORF1) modified antibody (Ab-MORF1) and human serum albumin conjugated with multiple copies of complementary morpholino oligonucleotide (MORF2), (HSA-(MORF2)x ). The two components recognize each Other via Watson-Crick base pairing complementation of their respective MORFs. One HSA-(MORF2)x molecule can hybridize with multiple Ab-MORF1 molecules on the cell surface, thus serving as the therapeutic crosslink-inducing mechanism of action. Herein, we examined various anti-neoplastic agents in combination with the anti-CD20 Obinutuzumab (OBN)-based DFMT system. We examined three different classes of chemotherapies: DNA alkylating agents; proliferation pathway inhibitors; and DNA replication inhibitors. We utilized Chou-Talalay combination index mathematics to determine which drugs engaged synergistically with OBN-based DFMT. We determined that OBN-based DFMT synergizes with Topoisomerase inhibitors and DNA nucleotide analogues but is antagonistic with proliferation pathway inhibitors. We performed cell mechanism experiments to analyze points of synergism or antagonism by investigating CA2+ influx, mitochondrial health, lysosomal stability, and cell cycle arrest. Finally, we demonstrated the synergistic drug combinatorial effects of OBN-based DFMT with etoposide in vivo using a human xenograft non-Hodgkin's lymphoma mouse model. This article is protected by copyright. All rights reserved.

Keywords

CD20 crosslinking; Chemo-immunotherapy; Drug-Free Macromolecular Therapeutics; Obinutuzumab; etoposide; human serum albumin.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》